TELCON RF PHARMACEUTICAL. EBIT

The latest EBIT for 200230.KQ is $6.2B as of June 2026. That compares with $-14B in the prior-year period — up 143.9% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside TELCON RF PHARMACEUTICAL.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 200230.KQ's EBIT moved from $-14B to $6.2B — a 143.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in TELCON RF PHARMACEUTICAL.'s operating scale or balance-sheet position.

Against its sector companies, 200230.KQ currently prints $6.2B for EBIT, while the sector average sits near $2.6T. That is roughly 99.8% below the sector mean. Large gaps often invite a closer look at TELCON RF PHARMACEUTICAL.'s growth, margins, and balance sheet.

A EBIT figure of $6.2B for 200230.KQ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting 200230.KQ's EBIT ($6.2B), review year-over-year change from $-14B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.